International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:
“Jarushka Naidoo at ELCC 2026, demonstrated that treatment with adagrasib was effective in fit patients aged 70 years and older with KRAS G12C-mutant NSCLC and provided quality-of-life benefits for those with poor performance status.
Other articles about IASLC on OncoDaily.